Newron Pharmaceuticals, SpA
Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Their lead compound, evenamide, is a first-in-class glutamate modulator in Phase III development, aiming to become the first add-on therapy for treatment-resistant schizophrenia. The company has a proven track record in CNS therapies, with their Parkinson’s treatment Xadago® (safinamide) approved in over 20 markets. They are committed to improving patients' quality of life through innovative treatments and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Newron Pharmaceuticals, SpA
Products
Investigational oral glutamate-modulating small molecule (lead candidate)
Oral small-molecule modulator of glutamate neurotransmission via selective voltage-gated sodium channel inhibition, developed as an add-on therapy for treatment-resistant and chronic schizophrenia; currently in late-stage clinical development.
Commercialized Parkinson's disease small-molecule therapy (historical asset)
Commercially approved small-molecule therapy for Parkinson's disease that the company previously developed and licensed for global commercialization by partners.
Investigational oral glutamate-modulating small molecule (lead candidate)
Oral small-molecule modulator of glutamate neurotransmission via selective voltage-gated sodium channel inhibition, developed as an add-on therapy for treatment-resistant and chronic schizophrenia; currently in late-stage clinical development.
Commercialized Parkinson's disease small-molecule therapy (historical asset)
Commercially approved small-molecule therapy for Parkinson's disease that the company previously developed and licensed for global commercialization by partners.
Services
Strategic partnering and licensing
Negotiation and management of territorial licensing and co-development agreements for CNS compounds; support for commercialization partnerships.
Clinical development collaborations
Co-development and collaboration with external CROs, KOLs and investigators to design and run CNS clinical trials and present data at scientific meetings.
Strategic partnering and licensing
Negotiation and management of territorial licensing and co-development agreements for CNS compounds; support for commercialization partnerships.
Clinical development collaborations
Co-development and collaboration with external CROs, KOLs and investigators to design and run CNS clinical trials and present data at scientific meetings.
Expertise Areas
- Clinical trial management
- CNS drug development
- Schizophrenia therapeutic development
- Global clinical operations
Key Technologies
- Small-molecule drug development
- Voltage-gated sodium channel modulation
- Glutamate-modulating mechanism of action
- Preclinical animal models of psychosis